Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial
Diabetes Care · 2023
DOI: 10.2337/dc22-1219 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2023. Verfasst von Ramzi A Ajjan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Population and Sciences Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Abbott Laboratories, National Institute for Health Research.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To analyze the impact of modern glucose-monitoring strategies on glycemic and patient-related outcomes in individuals with type 2 diabetes (T2D) and recent myocardial infarction (MI) and assess cost effectiveness. RESEARCH DESIGN AND METHODS LIBERATES was a multicenter two-arm randomized trial comparing self-monitoring of blood glucose (SMBG) with intermittently scanned continuous glucose monitoring (isCGM), also known as flash CGM, in individuals with T2D and recent MI, treated with insulin and/or a sulphonylurea before hospital admission. The primary outcome measure was time in range (TIR) (glucose 3.9–10 mmol/L/day) on days 76–90 post-randomization. Secondary and exploratory outcomes included time in hypoglycemia, hemoglobin A1c (HbA1c), clinical outcome, quality of life (QOL), and cost effectiveness. RESULTS Of 141 participants randomly assigned (median age 63 years; interquartile range 53, 70), 73% of whom were men, isCGM was associated with increased TIR by 17 min/day (95% credible interval −105 to +153 min/day), with 59% probability of benefit. Users of isCGM showed lower hypoglycemic exposure (<3.9 mmol/L) at days 76–90 (−80 min/day; 95% CI −118, −43), also evident at days 16–30 (−28 min/day; 95% CI −92, 2). Compared with baseline, HbA1c showed similar reductions of 7 mmol/mol at 3 months in both study arms. Combined glycemic emergencies and mortality occurred in four isCGM and seven SMBG study participants. QOL measures marginally favored isCGM, and the intervention proved to be cost effective. CONCLUSIONS Compared with SMBG, isCGM in T2D individuals with MI marginally increases TIR and significantly reduces hypoglycemic exposure while equally improving HbA1c, explaining its cost effectiveness. Studies are required to understand whether these glycemic differences translate into longer-term clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Population and Sciences Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
- Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, U.K.
- Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, U.K.
- Academic Unit of Health Economics, University of Leeds, Leeds, U.K.
- Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, U.K.
- School of Life and Medical Science, University of Hertfordshire, Hertfordshire, U.K.
ORCID-Profile: Ramzi A Ajjan, Simon R Heller
Förderung
- Abbott Laboratories
- National Institute for Health Research
Zitieren
APA
Ajjan, R. A., Heller, S. R., Everett, C. C., Vargas-Palacios, A., Higham, R., Sharples, L., Gorog, D. A., Rogers, A., Reynolds, C., Fernandez, C., Rodrigues, P., Sathyapalan, T., Storey, R. F., & Stocken, D. D. (2023). Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care. https://doi.org/10.2337/dc22-1219
Vancouver
Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care. 2023. doi:10.2337/dc22-1219
BibTeX
@article{Ajjan2023,
author = {Ajjan, Ramzi A and Heller, Simon R and Everett, Colin C and Vargas-Palacios, Armando and Higham, Ruchi and Sharples, Linda and Gorog, Diana A and Rogers, Alice and Reynolds, Catherine and Fernandez, Catherine and Rodrigues, Pedro and Sathyapalan, Thozhukat and Storey, Robert F and Stocken, Deborah D},
title = {Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial},
journal = {Diabetes Care},
year = {2023},
doi = {10.2337/dc22-1219}
}
EUVIMED